Table 1.
Target position | Screening for functional
mutations
|
Screening for dominant-negative mutations
|
||||
---|---|---|---|---|---|---|
Number examined | Number of Cs+ | Percentage of Cs+ | Number examined | Number of Sec− | Percentage of Sec− | |
Ser-349 | 58 | 45 | 78 | 282 | 3 | 1 |
Gly-350 | 42 | 16 | 40 | 340 | 3 | 1 |
Ala-351 | 28 | 20 | 73 | 298 | 20 | 7 |
Phe-352 | 64 | 30 | 48 | 358 | 17 | 5 |
Val-353 | 50 | 19 | 38 | 266 | 7 | 3 |
Pro-354 | 36 | 16 | 44 | 288 | 0 | 0 |
Gly-355 | 20 | 19 | 95 | 863 | 42 | 5 |
Ile-356 | 26 | 23 | 88 | 494 | 35 | 7 |
Arg-357 | 22 | 0 | 0 | 612 | 415 | 68 |
Pro-358 | 64 | 3 | 5 | 836 | 152 | 18 |
Gly-359 | 34 | 2 | 6 | 1,018 | 111 | 11 |
Glu-360 | 92 | 57 | 62 | 811 | 5 | 1 |
Gln-361 | 80 | 24 | 30 | 791 | 7 | 1 |
Thr-362 | 138 | 31 | 22 | 1,171 | 221 | 19 |
Ala-363 | 239 | 174 | 73 | 355 | 17 | 5 |
Lys-364 | 33 | 31 | 94 | 802 | 9 | 1 |
Tyr-365 | 23 | 22 | 96 | 729 | 12 | 2 |